Profile: Sequenom Inc (SQNM.OQ)

SQNM.OQ on NASDAQ Stock Exchange Global Select Market

3.29USD
30 Oct 2014
Price Change (% chg)

-- (--)
Prev Close
$3.29
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
394,014
52-wk High
$4.17
52-wk Low
$1.65

Search Stocks

Sequenom, Inc. (Sequenom), incorporated in 1994, is a molecular diagnostic testing and genetics analysis company committed to providing molecular diagnostic testing services, and research use only products, services, applications, and genetic analysis products that translate the results of genomic science into solutions for biomedical research, translational research, molecular medicine applications, and agricultural, livestock, and other areas of research. The Company’s development and commercialization efforts in various diagnostic areas include noninvasive women’s health-related and prenatal diagnostics, ophthalmology, and other medical conditions, such as oncology, infectious diseases and autoimmunity. The Company operates in two segments: Molecular Diagnostics (including Sequenom Center for Molecular Medicine, LLC, or Sequenom CMM) and Genetic Analysis. In November 2011, the Company entered into leases for additional laboratory and office space in San Diego, California and Durham, North Carolina. In May 2014, Sequenom Inc completed the sale of its Bioscience business to Agena Bioscience.

Molecular Diagnostics and SEQureDx Technology

The Company is engaged in researching, developing, and pursuing the commercialization of various noninvasive molecular diagnostic tests for prenatal genetic disorders, and diseases, women’s health-related disorders and diseases, ophthalmology, and other medical conditions such as oncology, infectious diseases, and autoimmunity. As of December 31, 2011, the Company is primarily focused on developing and commercializing prenatal diagnostic tests using its foundational, patent-protected, noninvasive, circulating cell-free fetal (ccff), nucleic acid-based assay technology, which the Company in-licensed from Isis Innovation Limited (Isis). The Company focuses on developing noninvasive in vitro diagnostic tests using its MassARRAY system and/or nucleic acid sequencing platforms provided by Illumina, Inc.

The Company is engaged in researching, developing, and pursuing the commercialization of various noninvasive molecular diagnostic tests for prenatal genetic disorders, and diseases, women’s health-related disorders and diseases, ophthalmology, and other medical conditions such as oncology, infectious diseases, and autoimmunity. As of December 31, 2011, the Company is primarily focused on developing and commercializing prenatal diagnostic tests using its foundational, patent-protected, noninvasive, circulating cell-free fetal (ccff), nucleic acid-based assay technology, which the Company in-licensed from Isis Innovation Limited (Isis). The Company focuses on developing noninvasive in vitro diagnostic tests using its MassARRAY system and/or nucleic acid sequencing platforms provided by Illumina, Inc.

Patient samples are collected by physicians and submitted to Sequenom CMM for testing and the results are reported back to the ordering physician. In February 2012, the MaterniT21 test was rebranded under the name MaterniT21 PLUS. Sequenom CMM developed, analytically validated, clinically validated in a multi-center international blinded study, and in October 2011, commercialized the MaterniT21 LDT for testing pregnant women who are at increased risk (by medical and clinical indicators) of carrying a fetus with trisomy 21. During the year ended December 31, 2011, the Diagnostics segment accounted 14.9% of the Company’s revenues.

Genetic Analysis

The Company’s MassARRAY system consists of hardware, software applications, and consumable chips and reagents. It is a high-performance nucleic acid analysis research use only platform that quantitatively and precisely measures genetic target material and variations. The Company’s research customers include clinical research laboratories, bioagriculture, biotechnology and pharmaceutical companies, academic institutions and various government agencies worldwide.

The Company’s MassARRAY system provides reliable results for a range of DNA/RNA analysis applications, including single nucleotide polymorphism (SNP), genotyping, detection of mutations, analysis of copy number variants, and other structural genome variations. In addition, the system provides quantitative gene expression analysis, quantitative DNA methylation analysis, comparative sequence analysis of haploid organisms, SNP discovery and oligonucleotide quality control. These applications are provided through research use application software that operates on the MassARRAY system and through the purchase of consumable chips and reagent sets. During 2011, the Genetic Analysis segment accounted 85.1% of the Company’s revenues.

The Company competes with Ikonysis, Inc., Verinata Health, Inc., Celula Inc., Fluidigm Corp., Aria Diagnostics, Inc., Natera, Life Technologies, Corp., Beckman Coulter, Inc., Illumina Inc., Biotage AB, Fluidigm Corp., Ibis Biosciences, Inc., Luminex and KBiosystems.

Company Address

Sequenom Inc

3595 John Hopkins Court
SAN DIEGO   CA   92121-1331
P: +1858.2029000
F: +1858.2029001

Search Stocks